Literature DB >> 20717646

[Classification and therapy of vasculitis according to recommendations of the European League Against Rheumatism (EULAR)].

J U Holle1, T Bley, W L Gross.   

Abstract

Vasculitis is still being classified according the criteria of the American College of Rheumatology and the Chapel Hill Consensus Conference Definitions. Diagnostic criteria are currently being established. The classification criteria are based on the size of the inflamed blood vessel (e.g. large vessel vasculitis with inflammation of the aorta and its branches), clinical symptoms and findings (such as cephalalgia in giant cell arteritis) and histological findings. In recent years a definition of disease stages and activity has been established and a number of controlled trials have been carried out in order to provide evidence-based stage and activity adapted therapy regimens. Recommendations for the management of vasculitis have been published in 2009 by EULAR (European League Against Rheumatism). This article gives a review of the classification of vasculitis and summarizes the current European guidelines on management.

Entities:  

Mesh:

Year:  2010        PMID: 20717646     DOI: 10.1007/s00117-010-2000-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  35 in total

1.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis.

Authors:  T A Bley; M Reinhard; C Hauenstein; M Markl; K Warnatz; A Hetzel; M Uhl; P Vaith; M Langer
Journal:  Arthritis Rheum       Date:  2008-08

3.  Polyarteritis nodosa: spectrum of angiographic findings.

Authors:  A W Stanson; J L Friese; C M Johnson; M A McKusick; J F Breen; E A Sabater; J C Andrews
Journal:  Radiographics       Date:  2001 Jan-Feb       Impact factor: 5.333

4.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

5.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 6.  Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.

Authors:  Philip J Klemmer; W Chalermskulrat; Michael S Reif; Susan L Hogan; David C Henke; Ronald J Falk
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

7.  Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study.

Authors:  F Moosig; N Czech; C Mehl; E Henze; R A Zeuner; M Kneba; J O Schröder
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

8.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

10.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.